Literature DB >> 31170814

Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients.

Joel M Michalski1, Elizabeth R Lyden1, Andrea J Lee1, Zaid S Al-Kadhimi1, Lori J Maness1, Krishna Gundabolu1, Vijaya Raj Bhatt1.   

Abstract

Aim: This study evaluated the overall survival (OS) of older patients (≥60 years) with acute myeloid leukemia based on the intensity of treatment.
Methods: This single center, retrospective study included 211 patients diagnosed between 2000 and 2016, who received 10-day decitabine, low-intensity therapy or high-intensity therapy. Cox regression examined the impact of therapy on OS.
Results: Younger patients were more likely to receive high-intensity therapy. Patients who received low-intensity therapy had worse OS compared with high-intensity therapy (median OS: 1.2 vs 8.5 months; p < 0.01). OS was similar with 10-day decitabine (median OS of 6.3 months) compared with either low-intensity therapy or high-intensity therapy.
Conclusion: Ten-day decitabine is an effective alternative in older patients with newly diagnosed acute myeloid leukemia.

Entities:  

Keywords:  10-day decitabine; acute myeloid leukemia; frail patients; hypomethylating agents; older adults; overall survival

Mesh:

Substances:

Year:  2019        PMID: 31170814      PMCID: PMC6714071          DOI: 10.2217/fon-2019-0001

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  25 in total

1.  Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.

Authors:  William Blum; Rebecca B Klisovic; Bjoern Hackanson; Zhongfa Liu; Shujun Liu; Hollie Devine; Tamara Vukosavljevic; Lenguyen Huynh; Gerard Lozanski; Cheryl Kefauver; Christoph Plass; Steven M Devine; Nyla A Heerema; Anthony Murgo; Kenneth K Chan; Michael R Grever; John C Byrd; Guido Marcucci
Journal:  J Clin Oncol       Date:  2007-08-06       Impact factor: 44.544

2.  The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.

Authors:  Mazin Al-Salihi; Margaret Yu; David M Burnett; Amanda Alexander; Wolfram E Samlowski; Frank A Fitzpatrick
Journal:  Epigenetics       Date:  2011-08-01       Impact factor: 4.528

3.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Authors:  William Blum; Ramiro Garzon; Rebecca B Klisovic; Sebastian Schwind; Alison Walker; Susan Geyer; Shujun Liu; Violaine Havelange; Heiko Becker; Larry Schaaf; Jon Mickle; Hollie Devine; Cheryl Kefauver; Steven M Devine; Kenneth K Chan; Nyla A Heerema; Clara D Bloomfield; Michael R Grever; John C Byrd; Miguel Villalona-Calero; Carlo M Croce; Guido Marcucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

4.  A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.

Authors:  Michael Lübbert; Björn H Rüter; Rainer Claus; Claudia Schmoor; Mathias Schmid; Ulrich Germing; Andrea Kuendgen; Volker Rethwisch; Arnold Ganser; Uwe Platzbecker; Oliver Galm; Wolfram Brugger; Gerhard Heil; Björn Hackanson; Barbara Deschler; Konstanze Döhner; Anne Hagemeijer; Pierre W Wijermans; Hartmut Döhner
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Authors:  Amanda F Cashen; Gary J Schiller; Margaret R O'Donnell; John F DiPersio
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

6.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

7.  Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Farhad Ravandi; Theresa Liu-Dumlao; Mark Brandt; Stefan Faderl; Sherry Pierce; Gautam Borthakur; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Blood       Date:  2012-10-15       Impact factor: 22.113

8.  Outcomes and quality of care in acute myeloid leukemia over 40 years.

Authors:  Shabbir M H Alibhai; Marc Leach; Mark D Minden; Joseph Brandwein
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

9.  Targeting DNA methylation.

Authors:  Jean-Pierre J Issa; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

10.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Authors:  Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Martin Höglund
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

View more
  4 in total

1.  Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.

Authors:  Vijaya R Bhatt; Valerie Shostrom; Sarah A Holstein; Zaid S Al-Kadhimi; Lori J Maness; Ann Berger; James O Armitage; Krishna Gundabolu
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-02-04

2.  Geriatric hematology research at the 2019 American Society of Hematology annual meeting: Young International Society of geriatric oncology perspective paper.

Authors:  Hira S Mian; Shakira J Grant; Smith Giri; Mazie Tsang; Reena V Jayani
Journal:  J Geriatr Oncol       Date:  2020-01-31       Impact factor: 3.599

3.  Efficacy of 10-day decitabine in acute myeloid leukemia.

Authors:  Ian M Bouligny; Vivek Mehta; Scott Isom; Leslie R Ellis; Rupali R Bhave; Dianna S Howard; Susan Lyerly; Megan Manuel; Sarah Dralle; Bayard L Powell; Timothy S Pardee
Journal:  Leuk Res       Date:  2021-02-12       Impact factor: 3.156

4.  Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.

Authors:  Yaping Chang; Gordon H Guyatt; Trevor Teich; Jamie L Dawdy; Shaneela Shahid; Jessica K Altman; Richard M Stone; Mikkael A Sekeres; Sudipto Mukherjee; Thomas W LeBlanc; Gregory A Abel; Christopher S Hourigan; Mark R Litzow; Laura C Michaelis; Shabbir M H Alibhai; Pinkal Desai; Rena Buckstein; Janet MacEachern; Romina Brignardello-Petersen
Journal:  PLoS One       Date:  2021-03-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.